U.S. Policy Drift And The Shift In Clinical Trial Supply Leadership
- May 21
- 1 min read
By: Dan Leonard, Executive Director, We Work For Health
Any driver knows the feeling of being passed on a highway.
Sometimes, you see the other car coming from a mile away; you might even change lanes to ease the overtake. Other times, a fellow commuter with a heavy foot emerges from seemingly nowhere, buzzing past audibly at an incredible speed.
China’s biopharmaceutical industry, souped up with state funding, a history of intellectual property appropriation, and an aggressive long-term strategy, just roared by the United States in a critical metric. A recent report from the GlobalData research firm confirmed that China, a country that has historically prioritized shortcuts over first-in-class drug development, suddenly leads the world in clinical trial volume.